GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ADC Therapeutics SA (NYSE:ADCT) » Definitions » Total Operating Expense

ADCT (ADC Therapeutics) Total Operating Expense : $194.73 Mil (TTM As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is ADC Therapeutics Total Operating Expense?

ADC Therapeutics's Total Operating Expense for the three months ended in Mar. 2025 was $49.16 Mil. ADC Therapeutics's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2025 was $194.73 Mil.

ADC Therapeutics Total Operating Expense Historical Data

The historical data trend for ADC Therapeutics's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ADC Therapeutics Total Operating Expense Chart

ADC Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only 218.68 293.88 329.59 232.08 194.48

ADC Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 48.91 44.91 52.91 47.75 49.16

ADC Therapeutics Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $194.73 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ADC Therapeutics Total Operating Expense Related Terms

Thank you for viewing the detailed overview of ADC Therapeutics's Total Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

ADC Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ADC Therapeutics SA (NYSE:ADCT) » Definitions » Total Operating Expense
Comparable Companies
FHTX RCKT ANNX TRDA RNAC ALLO INZY TNXP GOSS VNDA VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:UCB XBRU:ARGX ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
Route de la Corniche 3B, Biopole, Epalinges, CHE, 1066
Website
https://www.adctherapeutics.com
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).